Chimeric Antigen Receptor, or CAR T-cells, are genetically modified autologous T-cells that are currently used for immunotherapy to treat certain cancers.
These T-cells are modified to express CARs, which are proteins that allow T-cells to recognize an antigen on targeted tumor cells. Early outcomes from CAR T-cells trials have generated impressive results in patients with refractory or relapsed leukemias and lymphomas1-2, and research is underway on using CAR T-cells in solid tumors.
CAR T-cells are generated by collection whole blood from a patient and PBMC (peripheral blood mononuclear cells) are separated and saved while the remaining blood cells and components are returned to the body (leukapheresis). Next, T-cells are enriched from the PBMC population using various methods (e.g., density gradient, size-based fractionation, antibody bead conjugates).
The T-cells are genetically modified with genes of interest, such that they now express CARs, allowing them to target and destroy tumor cells. CAR T-cells are activated and expanded (ex vivo), and in production scale there are additional QA and transportation/delivery steps. Finally, CAR T-cells are infused back to the patient. This may be indirectly to the peripheral circulation or directly to the affected site depending on the tumor type.
The use of T-lymphocytes in adaptive immunotherapy is emerging as an important tool in the treatment of cancer and other clinical applications. Corning's™ Lymphocyte Serum Free Medium (88-551-CM) and Corning's™ Lymphocyte Serum Free Medium (88-581-CM) support the proliferation and activation of lymphocytes, including tumor infiltrating lymphocytes (TIL), Cytokine-Induced Killer (CIK) cells and Natural Killer (NK) cells. There is technical data to support the use in CAR-T as well as several other important immunotherapy applications.
T-cell isolation is the process of separating T-cells from other cell types in a biological sample. T-cells can be identified by surface markers like CD3, CD4, and CD8. Cell separation is a critical step in the research process.
Whether you're expanding suspension or adherent cell lines, we offer a full range of cell culture vessels, from 75 mL T-flasks to 50L rocker bags. Our broad and comprehensive portfolio of quality-controlled cell culture vessels allows you to seamlessly scale up with the peace of mind that the products you start with will be suitable for regulated drug manufacturing environments downstream.
Following your scale-up process, it is time to harvest your cells and prepare to move to downstream manufacturing steps or to cryopreserve cells. For cell processing, Corning offers closed system solutions to ensure a contamination-free filtration process. These closed system solutions are ready-to-use, eliminating the time and expense of sourcing and assembling your own closed system. Couple that with sterility assurance and manufacturing compliance, and you have all the tools you need to customize a process to streamline a viable cell collection. For freezing and preserving your cell therapy collection, Corning offers a portfolio of cryogenic storage products, from Corning CoolCell controlled-rate, alcohol-free cell freezing systems to cryogenic vials and bags, all designed to protect your valuable cell lines.
Corning offers a comprehensive range of innovative, high-quality tools and solutions for life science research and bioproduction. All Corning brands offer consistent, reliable and repeatable results giving you the confidence that you can only get with almost 100 years of expertise in research, product development and manufacturing.
Life Sciences products include consumables (such as plastic vessels, speciality surfaces, cell culture media and serum), as well as general labware and equipment, that are used for advanced cell culture research, bioprocessing, genomics, drug disovery, microbioloby and chemistry. Corning sells life sciences products under these primary brands: Corning™, Falcon™, Axygen™ and Corning Gosselin™.
Supplier Partner